Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD L WASSERMAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1346234614
CMS profile
151902
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$119,905.09

118 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Grifols USA, LLC $64,169.50 49
GlaxoSmithKline, LLC. $38,569.01 31
CSL Behring $9,936.57 15
Takeda Pharmaceuticals U.S.A., Inc. $4,056.15 3
GENZYME CORPORATION $2,836.50 4
PFIZER INC. $160.20 7
Octapharma USA, Inc. $44.79 2
Pharming Healthcare, Inc. $41.79 2
kaleo, Inc. $23.09 1
BioCryst US Sales Co., LLC $21.62 1
TerSera Therapeutics LLC $16.53 1
Phadia US Inc. $15.22 1
AstraZeneca Pharmaceuticals LP $14.12 1

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD L WASSERMAN

NPI 1346234614 · CMS profile ID 151902

Allopathic & Osteopathic Physicians / Allergy & Immunology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346234614?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD L WASSERMAN, NPI 1346234614, CMS profile ID 151902. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346234614?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RICHARD L WASSERMAN, NPI 1346234614, CMS profile ID 151902. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346234614?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RICHARD L WASSERMAN, NPI 1346234614, CMS profile ID 151902, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346234614?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

118 matching records · $119,905.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 118 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 118.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $1,300.0009/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210513 CMS
Takeda Pharmaceuticals U.S.A., Inc. $31.1509/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055661317 CMS
GlaxoSmithKline, LLC. $58.1109/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209981 CMS
GlaxoSmithKline, LLC. $1,300.0009/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211161 CMS
Grifols USA, LLC $42.5509/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762277 CMS
GlaxoSmithKline, LLC. $1,300.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209969 CMS
GlaxoSmithKline, LLC. $1,300.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210049 CMS
Grifols USA, LLC $35.0908/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762105 CMS
Grifols USA, LLC $51.8908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762111 CMS
PFIZER INC. $28.8508/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050639249 CMS
GlaxoSmithKline, LLC. $1,300.0008/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210085 CMS
GlaxoSmithKline, LLC. $1,300.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209471 CMS
GlaxoSmithKline, LLC. $1,300.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211125 CMS
GlaxoSmithKline, LLC. $1,300.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209458 CMS
GlaxoSmithKline, LLC. $1,300.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210467 CMS
CSL Behring $600.0006/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972310 CMS
PFIZER INC. $9.3406/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050581839 CMS
GlaxoSmithKline, LLC. $1,300.0006/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001211101 CMS
Grifols USA, LLC $4,950.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762211 CMS
Grifols USA, LLC $61.1106/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762217 CMS
GlaxoSmithKline, LLC. $14.7505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001209493 CMS
Grifols USA, LLC $348.5605/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762223 CMS
Grifols USA, LLC $186.9605/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762229 CMS
Pharming Healthcare, Inc. $21.7505/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029353579 CMS
BioCryst US Sales Co., LLC $21.6205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012568967 CMS
Grifols USA, LLC $6,300.0005/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762300 CMS
Grifols USA, LLC $283.5905/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762305 CMS
Grifols USA, LLC $150.6205/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762309 CMS
Grifols USA, LLC $47.9605/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762315 CMS
PFIZER INC. $21.2204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050554289 CMS
AstraZeneca Pharmaceuticals LP $14.1204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025043967 CMS
Grifols USA, LLC $30.7704/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762235 CMS
Grifols USA, LLC $3,500.0004/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762241 CMS
Grifols USA, LLC $282.8304/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762247 CMS
Grifols USA, LLC $10.0004/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762253 CMS
Grifols USA, LLC $13.5104/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762259 CMS
Grifols USA, LLC $24.2804/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762265 CMS
Grifols USA, LLC $50.0004/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011762271 CMS
CSL Behring $60.9204/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972095 CMS
CSL Behring $7.0004/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972109 CMS
CSL Behring $5.0004/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972119 CMS
CSL Behring $2,700.0004/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972143 CMS
PFIZER INC. $22.7204/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049204873 CMS
CSL Behring $121.8403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042972085 CMS
GlaxoSmithKline, LLC. $1,300.0003/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210525 CMS
PFIZER INC. $22.7803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050451777 CMS
GlaxoSmithKline, LLC. $3,900.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001210605 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,625.0002/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055661311 CMS
Phadia US Inc. $15.2202/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 971749465 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,400.0002/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055661305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47,503.53 66
PY2020 $40,725.97 36
PY2021 $98,619.74 77
PY2022 $73,782.37 73
PY2023 $119,905.09 118
PY2024 $55,848.44 73
PY2025 $15,659.61 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $320,196.32 60
PY2024 Principal investigator $233,663.76 46
PY2023 Recipient $44,840.60 57
PY2022 Principal investigator $57,475.21 16
PY2021 Principal investigator $220,143.13 31
PY2020 Principal investigator $285,821.34 23
PY2019 Principal investigator $333,779.63 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,726.00 12/19/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223289950
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,969.64 12/19/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223289952
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18.24 12/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223289220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,250.00 12/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223289222
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,136.00 11/25/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288737
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,363.00 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288299
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $239.15 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,654.76 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288305
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,782.00 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $206.52 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,478.00 11/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223288313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,395.00 10/23/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223287375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,136.00 10/23/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223287377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,502.00 10/16/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223287037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,902.00 10/03/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223286271
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,872.00 09/18/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285650
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,447.00 09/18/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285652
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,672.00 09/12/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,136.00 09/12/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,724.00 08/26/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223284585
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,230.00 07/22/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282898
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,448.00 07/22/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282900
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,402.00 07/14/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282604
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 07/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282228
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $984.48 07/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282244
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,328.93 06/12/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281094
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $253.07 06/12/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,254.00 06/12/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281144
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,376.00 06/05/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280770
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280522
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280526
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,602.00 05/22/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,948.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278656
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,376.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278658
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278660
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278662
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278664
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278666
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 04/28/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278668
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,376.00 04/23/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278558
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,672.00 04/23/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,724.00 04/15/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278066
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,666.00 04/01/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223277210
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,376.00 03/25/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223276971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,672.00 03/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223275909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,336.00 02/25/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223275521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,724.00 02/05/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274769
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 02/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274713
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 02/04/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,896.00 01/29/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,001.21 01/29/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/29/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274543
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 01/22/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF NORTH TEXAS
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274271
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,168.00 01/21/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,444.00 01/07/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273649
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,050.00 01/07/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,542.08 01/07/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $137.24 01/07/2025 Non-covered Recipient Entity
ALLERGY PARTNERS OF TEXAS INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273655

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $1,992.50 1
PY2025 Value of interest $1,992.50 1
PY2024 Amount invested $1,992.50 1
PY2024 Value of interest $1,992.50 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Consortium of Independent Immunology Clinics, LLC $1,992.50 $1,992.50 n/a Physician Covered Recipient No dispute reported 06/30/2026 1228219647
PY2024 Consortium of Independent Immunology Clinics, LLC $1,992.50 $1,992.50 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147193579